0.13Open0.13Pre Close0 Volume8 Open Interest105.00Strike Price0.00Turnover130.99%IV57.18%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.0044Delta0.0002Gamma1883.77Leverage Ratio-0.0202Theta-0.0007Rho-8.28Eff Leverage0.0084Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet